Tesla Motors, Inc. (NASDAQ: TSLA), BYD CO LTD H SHS (BYDDF) – Tesla’s February sales growth in China shows ‘large directional fluctuation’, says analyst

Tesla, Inc. (NASDAQ: TSLA) defied the odds and reported a month-over-month increase in deliveries in February, according to data released by the China Passenger Car Association.

Tesla analyst: Wedbush analyst Daniel Ives has a neutral rating and a target price of $ 950 for Tesla shares.

Tesla’s Thesis: Tesla delivered 18,300 vehicles to China in February, representing an 18% increase from January and signaling a decline in demand for Tesla in the key region of China, Ives said in a note.

All three Chinese electric vehicle manufacturers listed in the U.S. reported last week drop in deliveries from February to month.

The month-on-month growth for Tesla is impressive, given that it occurred despite the Lunar New Year holidays in China taking up a significant part of February, the analyst said.

Related link: Tesla reaches a high price of $ 1,200: ‘The fireworks are not over yet’

The company is expected to achieve an annual run rate of more than 200,000 units in China by 2021, which remains a key element in achieving global deliveries of 750,000-800,000 units for the year, he said.

From the unit’s point of view, Tesla’s month-on-month growth in deliveries – as opposed to declines reported by BYD Company Limited (OTC: BYDDF), Nio Inc – ADR (NYSE: NIO) and XPeng Inc – ADR (NYSE: XPEV) and Li Auto Inc. (NASDAQ: LI) – signals a large directional fluctuation in market share, said Ives.

Price cuts and the introduction of Model Y are fundamental to some of the changing market dynamics in China, the analyst said.

TSLA Price Action: Tesla’s shares were up 19.53% to $ 672.94 in the last scan on Tuesday.

Photo courtesy of Tesla.

Most recent reviews of TSLA

Meeting Company Action From For
March 2021 New street Upgrades Neutral Purchase
February 2021 Morgan Stanley Keeps Overweight
February 2021 Piper Sandler Keeps Overweight

See more analyst reviews for TSLA

See the latest analyst reviews

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Source